Optimer Pharma (OPTR) Names Hank McKinnell as Chairman; Sees Q1 Revs Below Views
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Financial Fact:
Interest income and other, net: 249.12K
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Interest income and other, net: 249.12K
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Optimer Pharmaceuticals (Nasdaq: OPTR) has appointed Hank McKinnell as its new Chairman. Dr. McKinnell was previously appointed Lead Independent Director at the February 29, 2012 Board meeting. The Company also announced that Kurt Hartman – who currently serves as General Counsel, Chief Compliance Officer and Senior Vice President – has been appointed acting CFO and a search for a permanent CFO has commenced.
The appointments were made after the Optimer Board of Directors removed Dr. Michael Chang as Chairman and terminated John D. Prunty, Chief Financial Officer, and Dr. Youe-Kong Shue, Vice President. The Board, excluding Dr. Chang, unanimously approved the personnel changes. The Company said that Dr. Chang remains as a Director of the Company, but that the Board has requested his resignation.
The changes are not expected to materially impact the Company's revenues or operations, including the commercialization and launch of DIFICID®, but were related to certain lapses in corporate governance practices and the Company's relationship with Optimer Biotechnology, Inc. ("OBI"), its 43%-owned independent, Taiwanese-based affiliate.
Separately, the Company announced that, based upon preliminary results, it expects to report gross revenues of approximately $16.45 million for the first quarter of 2012, an increase of approximately 36% over gross revenues for the fourth quarter of 2011.
The Street sees revs of $29.4 million.
The appointments were made after the Optimer Board of Directors removed Dr. Michael Chang as Chairman and terminated John D. Prunty, Chief Financial Officer, and Dr. Youe-Kong Shue, Vice President. The Board, excluding Dr. Chang, unanimously approved the personnel changes. The Company said that Dr. Chang remains as a Director of the Company, but that the Board has requested his resignation.
The changes are not expected to materially impact the Company's revenues or operations, including the commercialization and launch of DIFICID®, but were related to certain lapses in corporate governance practices and the Company's relationship with Optimer Biotechnology, Inc. ("OBI"), its 43%-owned independent, Taiwanese-based affiliate.
Separately, the Company announced that, based upon preliminary results, it expects to report gross revenues of approximately $16.45 million for the first quarter of 2012, an increase of approximately 36% over gross revenues for the fourth quarter of 2011.
The Street sees revs of $29.4 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Robo.ai names Hao Wang of Changer.ae to its board of directors
- Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
- Target (TGT) Tops Q2 EPS by $1.78, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Guidance, Hot Guidance, Management Changes, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
